Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 155   

Articles published

NVS 72.70 +0.50 (0.69%)
price chart
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.
Could Novartis AG (ADR) See a Reversal After Having a Gap Up Today?
The stock of Novartis AG (ADR) (NYSE:NVS) gapped up by $0.17 today and has $109.53 target or 49.00% above today's $73.51 share price.
Analyst's Ratings Review: Novartis AG  CWRU Observer
Novartis AG (ADR) (NVS) Earnings Per Share Expected to Increase
Analysts await Novartis AG (ADR) (NYSE:NVS) to reports earnings on October, 27. They expect $1.32 EPS, up 3.13% or $0.04 from last year's $1.28 per share.
Novartis AG (ADR) (NVS) Stock Update: September Begins With Multiple Deals And ...
Novartis AG (ADR) (NYSE:NVS) has seen an eventful first week of September. The company struck a partnership deal with biotech giant Amgen, Inc. (NASDAQ:AMGN) and won regulatory approvals for several drugs in both the US and Europe - all during the ...
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Will Novartis And Pharma Giants Provide Alzheimer's Cure?
Novartis AG (ADR) (NYSE:NVS) and other market leaders are trying their best in the development of a novel drug for the comprehensive treatment of Alzheimer's disease.
Trade of the Day: It's Not Too Late to Short NVS Stock
Novartis AG (ADR) (NVS) - I last featured NVS stock as the Trade of the Day on Oct. 1, recommending traders sell shares short at $95 with a downside target of $85.
Revenue Update on Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during Pre-market on Jan 27, 2016.
Analyst Price Target on Novartis AG  Analyst Rating Reports
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million
Novartis AG ADR (NYSE:NVS) has agreed to acquire Spinifex Pharmaceuticals, a US-Australian pain management biotech company, to strengthen its position in the pain management market, according to separate statements released by both companies ...
Novartis AG (ADR) (NVS) To Acquire Spinifex  Business Finance News